Results 291 to 300 of about 207,548 (354)

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy. [PDF]

J Clin Oncol
Petrylak DP, Tagawa ST, Jain RK, Bupathi M, Balar A, Kalebasty AR, George S, Palmbos P, Nordquist L, Davis N, Ramamurthy C, Sternberg CN, Loriot Y, Agarwal N, Park C, Tonelli J, Vance M, Zhou H, Grivas P.   +18 more
europepmc   +1 more source

v. 15, no. 13, April 27, 1956 [PDF]

, 1956

core   +1 more source

Listen to your feet. [PDF]

J Physiol
Macefield VG.
europepmc   +1 more source

What motivates participants: a qualitative analysis of gamification and financial incentives to increase physical activity. [PDF]

BMC Public Health
Ryu E, Farraday D, Fanaroff AC, Coratti S, Chokshi NP, Zhu J, Szymczak JE, Russell LB, Norton L, Small D, Volpp KG, Klaiman T.   +11 more
europepmc   +1 more source

Clinical perspective on management of key adverse events with sacituzumab govitecan. [PDF]

Oncologist
Tolaney SM, Sonpavde GP, Tarantino P, Lustberg MB, Rugo HS.   +4 more
europepmc   +1 more source

A plain language summary of the TROPiCS-04 study: sacituzumab govitecan use after platinum-based chemotherapy and immunotherapy in people with locally advanced or metastatic cancer of the bladder, urethra, or upper urinary tract. [PDF]

Future Oncol
Powles T, Tagawa ST, Vulsteke C, Gross-Goupil M, Park SH, Necchi A, De Santis M, Duran I, Morales-Barrera R, Guo J, Sternberg CN, Bellmunt J, Goebell PJ, Kovalenko M, Boateng F, Sierecki M, Wang L, Sima CS, Waldes J, Bangs R, Loriot Y, Grivas P.   +21 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Trophis

2022
Taxonomic treatment for ...
openaire   +1 more source